Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020;22:74–9. https://doi.org/10.1016/j.micinf.2020.01.003.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708–20. https://doi.org/10.1056/NEJMoa2002032.

Article  PubMed  CAS  Google Scholar 

Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–45. https://doi.org/10.1016/S2352-3026(20)30251-9.

Article  PubMed  PubMed Central  Google Scholar 

Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168. https://doi.org/10.1186/s13045-021-01177-0.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for Cancer. N Engl J Med. 2020;383:2586–8. https://doi.org/10.1056/NEJMc2031670.

Article  PubMed  CAS  Google Scholar 

Lee CY, Shah MK, Hoyos D, et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022;12:62–73. https://doi.org/10.1158/2159-8290.CD-21-1033.

Article  PubMed  CAS  Google Scholar 

Dulery R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96:934–44. https://doi.org/10.1002/ajh.26209.

Article  PubMed  PubMed Central  CAS  Google Scholar 

McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33. https://doi.org/10.1200/JCO.1998.16.8.2825.

Article  PubMed  CAS  Google Scholar 

Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-hodgkin’s lymphoma. Blood. 1997;90:2188–95.

Article  PubMed  CAS  Google Scholar 

Tudesq JJ, Cartron G, Riviere S, et al. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmun Rev. 2018;17:115–24. https://doi.org/10.1016/j.autrev.2017.11.015.

Article  PubMed  CAS  Google Scholar 

Loarce-Martos J, Garcia-Fernandez A, Lopez-Gutierrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40:2015–21. https://doi.org/10.1007/s00296-020-04699-x.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hoffmann MS, Ganguly S, Delayed. COVID-19 respiratory failure in patients with lymphoma on Rituximab-based Chemoimmunotherapy. Clin Lymphoma Myeloma Leuk. 2021;21:e548–50. https://doi.org/10.1016/j.clml.2021.02.009.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Calderon-Parra J, Munez-Rubio E, Fernandez-Cruz A, et al. Incidence, clinical presentation, relapses and outcome of severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in patients treated with Anti-CD20 monoclonal antibodies. Clin Infect Dis. 2022;74:1786–94. https://doi.org/10.1093/cid/ciab700.

Article  PubMed  CAS  Google Scholar 

Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011;152:295–306. https://doi.org/10.1111/j.1365-2141.2010.08428.x.

Article  PubMed  CAS  Google Scholar 

Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031–42. https://doi.org/10.1158/1535-7163.MCT-12-1182.

Article  PubMed  CAS  Google Scholar 

Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–402. https://doi.org/10.1182/blood-2009-06-225979.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182:29–45. https://doi.org/10.1111/bjh.15232.

Article  PubMed  Google Scholar 

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

Article  PubMed  CAS  Google Scholar 

In Coronavirus Disease 2019 (COVID-19) treatment guidelines; Bethesda (MD), 2021.

Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel). 2015;7:305–28. https://doi.org/10.3390/cancers7010305.

Article  PubMed  CAS  Google Scholar 

Ghielmini M, Rufibach K, Salles G, et al. Single agent Rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2005;16:1675–82. https://doi.org/10.1093/annonc/mdi320.

Article  PubMed  CAS  Google Scholar 

Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13:106–11. https://doi.org/10.1016/j.clml.2012.11.011.

Article  PubMed  CAS  Google Scholar 

Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer. 2007;109:2182–9. https://doi.org/10.1002/cncr.22666.

Article  PubMed  CAS  Google Scholar 

Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with Rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706–14. https://doi.org/10.1093/jnci/djk152.

Article  PubMed  CAS  Google Scholar 

Shafat T, Grupel D, Porges T, Levi I, Yagel Y, Nesher L. Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19. Br J Haematol. 2022;198:826–9. https://doi.org/10.1111/bjh.18315.

Article  PubMed  CAS  Google Scholar 

Aurer I, Jaksic O, Basic-Kinda S, et al. Treatment-related risk factors for adverse outcomes of COVID-19 in patients treated for lymphoid malignancies in the Pre-omicron Era-A study of KroHem, the Croatian Group for Hematologic Diseases. Biomedicines. 2024;12. https://doi.org/10.3390/biomedicines12020331.

Hill BT, Nastoupil L, Winter AM, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019;184:524–35. https://doi.org/10.1111/bjh.15720.

Article  PubMed  CAS  Google Scholar 

Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377:1331–44. https://doi.org/10.1056/NEJMoa1614598.

Article  PubMed